EP0511270A1 - New thiazole derivatives - Google Patents
New thiazole derivativesInfo
- Publication number
- EP0511270A1 EP0511270A1 EP91902804A EP91902804A EP0511270A1 EP 0511270 A1 EP0511270 A1 EP 0511270A1 EP 91902804 A EP91902804 A EP 91902804A EP 91902804 A EP91902804 A EP 91902804A EP 0511270 A1 EP0511270 A1 EP 0511270A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ppm
- substituted
- multiplet
- singlet
- bromo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007979 thiazole derivatives Chemical class 0.000 title description 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 17
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000002357 guanidines Chemical class 0.000 claims abstract description 8
- 230000007062 hydrolysis Effects 0.000 claims abstract description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 6
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 4
- 230000000172 allergic effect Effects 0.000 claims abstract description 4
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 238000006698 hydrazinolysis reaction Methods 0.000 claims abstract description 3
- 125000005544 phthalimido group Chemical group 0.000 claims abstract description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- -1 5H-dibenzo-[a,d]-cyclohepten-5-yl group Chemical group 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 229960001340 histamine Drugs 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 13
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 3
- 238000005893 bromination reaction Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 238000007363 ring formation reaction Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 56
- 238000005160 1H NMR spectroscopy Methods 0.000 description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 36
- 238000003756 stirring Methods 0.000 description 36
- 238000001816 cooling Methods 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 238000002844 melting Methods 0.000 description 21
- 230000008018 melting Effects 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- 229960004132 diethyl ether Drugs 0.000 description 20
- 239000000203 mixture Substances 0.000 description 18
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000012299 nitrogen atmosphere Substances 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- 238000001819 mass spectrum Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 235000011167 hydrochloric acid Nutrition 0.000 description 9
- 229960000443 hydrochloric acid Drugs 0.000 description 9
- IFPPZTSKNBSMHN-UHFFFAOYSA-N 2-(3-bromo-4-oxopentyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCC(Br)C(=O)C)C(=O)C2=C1 IFPPZTSKNBSMHN-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 229910010272 inorganic material Inorganic materials 0.000 description 8
- 239000011147 inorganic material Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- KKKXIWVOUGTUNV-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]-1-(3,3-diphenylpropyl)guanidine 2,4,6-trinitrophenol Chemical compound C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.NC=1SC(=C(N1)C)CCCNC(=N)NCCC(C1=CC=CC=C1)C1=CC=CC=C1 KKKXIWVOUGTUNV-UHFFFAOYSA-N 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 230000008570 general process Effects 0.000 description 7
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 7
- 150000003557 thiazoles Chemical class 0.000 description 7
- FWNCNQDIENYPDJ-UHFFFAOYSA-N 2-(4-hydroxybutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCO)C(=O)C2=C1 FWNCNQDIENYPDJ-UHFFFAOYSA-N 0.000 description 6
- LZJDEPWZKBPSRS-UHFFFAOYSA-N 2-(4-methyl-1,3-thiazol-5-yl)ethanamine;dihydrochloride Chemical compound Cl.Cl.CC=1N=CSC=1CCN LZJDEPWZKBPSRS-UHFFFAOYSA-N 0.000 description 6
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical compound C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 description 6
- LHVRFUVVRXGZPV-UHFFFAOYSA-N 5-(2-aminoethyl)-4-methyl-2-thiazolamine Chemical compound CC=1N=C(N)SC=1CCN LHVRFUVVRXGZPV-UHFFFAOYSA-N 0.000 description 6
- NFHWLPHEKVZKQU-UHFFFAOYSA-N 5-(3-aminopropyl)-4-methyl-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.CC=1N=C(N)SC=1CCCN NFHWLPHEKVZKQU-UHFFFAOYSA-N 0.000 description 6
- CZGOECYPTLSLNI-UHFFFAOYSA-N 6-bromohexan-2-one Chemical compound CC(=O)CCCCBr CZGOECYPTLSLNI-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000000543 Histamine Receptors Human genes 0.000 description 6
- 108010002059 Histamine Receptors Proteins 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002178 crystalline material Substances 0.000 description 6
- 229940093499 ethyl acetate Drugs 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- HVVRQUYSKYIOJV-UHFFFAOYSA-N 2-(5-oxohexyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCC(=O)C)C(=O)C2=C1 HVVRQUYSKYIOJV-UHFFFAOYSA-N 0.000 description 5
- VKPJPAPCRZIUMA-UHFFFAOYSA-N 2-[3-(1h-imidazol-5-yl)propyl]guanidine Chemical group NC(N)=NCCCC1=CN=CN1 VKPJPAPCRZIUMA-UHFFFAOYSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 5
- KZZIVOLMJPSDEP-UHFFFAOYSA-N 1-[3-(4-fluorophenyl)-3-pyridin-2-ylpropyl]-2-[3-(1h-imidazol-5-yl)propyl]guanidine Chemical compound C=1N=CNC=1CCCN=C(N)NCCC(C=1N=CC=CC=1)C1=CC=C(F)C=C1 KZZIVOLMJPSDEP-UHFFFAOYSA-N 0.000 description 4
- ONTXCMXICQNNNO-UHFFFAOYSA-N 2-(3-oxobutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCC(=O)C)C(=O)C2=C1 ONTXCMXICQNNNO-UHFFFAOYSA-N 0.000 description 4
- VIHXJMXDYXZGGL-UHFFFAOYSA-N 2-(4-bromo-5-oxohexyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCC(Br)C(=O)C)C(=O)C2=C1 VIHXJMXDYXZGGL-UHFFFAOYSA-N 0.000 description 4
- SLTUYEGLKJHGHO-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]-1-cyano-3-(3,3-diphenylpropyl)guanidine Chemical compound N1=C(N)SC(CCCN=C(NCCC(C=2C=CC=CC=2)C=2C=CC=CC=2)NC#N)=C1C SLTUYEGLKJHGHO-UHFFFAOYSA-N 0.000 description 4
- SUALZDCPKLVMJL-UHFFFAOYSA-N 5-(3-aminopropyl)-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.NCCCC1=CN=C(N)S1 SUALZDCPKLVMJL-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- SLIKWVTWIGHFJE-UHFFFAOYSA-N diphenoxymethylidenecyanamide Chemical compound C=1C=CC=CC=1OC(=NC#N)OC1=CC=CC=C1 SLIKWVTWIGHFJE-UHFFFAOYSA-N 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 150000002541 isothioureas Chemical class 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PTPZBCHKQSHXQZ-UHFFFAOYSA-N 2-(4-bromo-3-oxobutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCC(=O)CBr)C(=O)C2=C1 PTPZBCHKQSHXQZ-UHFFFAOYSA-N 0.000 description 3
- DPATUMDQWSJANG-UHFFFAOYSA-N 2-(4-oxopentyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCC(=O)C)C(=O)C2=C1 DPATUMDQWSJANG-UHFFFAOYSA-N 0.000 description 3
- PSKJVCNFAMZUFJ-UHFFFAOYSA-N 2-(5-bromo-4-oxopentyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCC(=O)CBr)C(=O)C2=C1 PSKJVCNFAMZUFJ-UHFFFAOYSA-N 0.000 description 3
- IPOCGIVMVZXNBQ-UHFFFAOYSA-N 2-[2-(2-amino-1,3-thiazol-4-yl)ethyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.S1C(N)=NC(CCN2C(C3=CC=CC=C3C2=O)=O)=C1 IPOCGIVMVZXNBQ-UHFFFAOYSA-N 0.000 description 3
- JASQWGXCYJFBDS-UHFFFAOYSA-N 2-[2-(4-methyl-1,3-thiazol-5-yl)ethyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.N1=CSC(CCN2C(C3=CC=CC=C3C2=O)=O)=C1C JASQWGXCYJFBDS-UHFFFAOYSA-N 0.000 description 3
- QAZIDPZKBKDKHT-UHFFFAOYSA-N 2-[3-(2-amino-1,3-thiazol-4-yl)propyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.S1C(N)=NC(CCCN2C(C3=CC=CC=C3C2=O)=O)=C1 QAZIDPZKBKDKHT-UHFFFAOYSA-N 0.000 description 3
- WNNXALBEELVCMI-UHFFFAOYSA-N 2-bromo-5-(1,3-dioxoisoindol-2-yl)pentanal Chemical compound C1=CC=C2C(=O)N(CCCC(Br)C=O)C(=O)C2=C1 WNNXALBEELVCMI-UHFFFAOYSA-N 0.000 description 3
- BHCHUXXNTHWMGJ-UHFFFAOYSA-N 4-(3-aminopropyl)-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.NCCCC1=CSC(N)=N1 BHCHUXXNTHWMGJ-UHFFFAOYSA-N 0.000 description 3
- NQUYKSNCKIXTQF-UHFFFAOYSA-N 5-(2-aminoethyl)-4-methyl-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.CC=1N=C(N)SC=1CCN NQUYKSNCKIXTQF-UHFFFAOYSA-N 0.000 description 3
- SMIKUIMODNMCCG-UHFFFAOYSA-N C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.NC=1SC=C(N1)CCCNC(=N)NCCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.NC=1SC=C(N1)CCCNC(=N)NCCC(C1=CC=CC=C1)C1=CC=CC=C1 SMIKUIMODNMCCG-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- HSYTXMUILWZKFF-UHFFFAOYSA-N 1-[2-(2-amino-4-methyl-1,3-thiazol-5-yl)ethyl]-3-cyano-2-(3,3-diphenylpropyl)guanidine Chemical compound N1=C(N)SC(CCNC(NC#N)=NCCC(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C HSYTXMUILWZKFF-UHFFFAOYSA-N 0.000 description 2
- XTRFUKPSMUKNJF-UHFFFAOYSA-N 1-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]-3-cyano-2-methylguanidine Chemical compound N#CNC(=NC)NCCCC=1SC(N)=NC=1C XTRFUKPSMUKNJF-UHFFFAOYSA-N 0.000 description 2
- ZPLDPSXWSZPAQP-UHFFFAOYSA-N 2-(2,4-dimethyl-1,3-thiazol-5-yl)ethanamine;dihydrochloride Chemical compound Cl.Cl.CC1=NC(C)=C(CCN)S1 ZPLDPSXWSZPAQP-UHFFFAOYSA-N 0.000 description 2
- GZOILRFVMJAQBC-UHFFFAOYSA-N 2-(3-bromo-4-hydroxybutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCC(Br)CO)C(=O)C2=C1 GZOILRFVMJAQBC-UHFFFAOYSA-N 0.000 description 2
- AEQXSCZKSNBLQW-UHFFFAOYSA-N 2-(5-hydroxypentyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCCO)C(=O)C2=C1 AEQXSCZKSNBLQW-UHFFFAOYSA-N 0.000 description 2
- TTYYVHIMEKPWIW-UHFFFAOYSA-N 2-[2-(2,4-dimethyl-1,3-thiazol-5-yl)ethyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.S1C(C)=NC(C)=C1CCN1C(=O)C2=CC=CC=C2C1=O TTYYVHIMEKPWIW-UHFFFAOYSA-N 0.000 description 2
- FQEIHIVPLCDSGY-UHFFFAOYSA-N 2-[3-(2-amino-1,3-thiazol-5-yl)propyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.S1C(N)=NC=C1CCCN1C(=O)C2=CC=CC=C2C1=O FQEIHIVPLCDSGY-UHFFFAOYSA-N 0.000 description 2
- DNLARIARHLWZRF-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]-1-(3,3-diphenylpropyl)guanidine Chemical compound N1=C(N)SC(CCCN=C(N)NCCC(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C DNLARIARHLWZRF-UHFFFAOYSA-N 0.000 description 2
- PIEKTEFCFGGLCN-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]-1-cyano-3-(3-phenylbutyl)guanidine Chemical compound C=1C=CC=CC=1C(C)CCNC(NC#N)=NCCCC=1SC(N)=NC=1C PIEKTEFCFGGLCN-UHFFFAOYSA-N 0.000 description 2
- BNCFKRVOUNWXAY-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-3-pyridin-2-ylpropan-1-amine Chemical compound C=1C=CC=NC=1C(CCN)C1=CC=C(Cl)C(Cl)=C1 BNCFKRVOUNWXAY-UHFFFAOYSA-N 0.000 description 2
- HEGXJUJXMQAWMZ-UHFFFAOYSA-N 4-(2-aminoethyl)-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.NCCC1=CSC(N)=N1 HEGXJUJXMQAWMZ-UHFFFAOYSA-N 0.000 description 2
- LZHGBLUAJMICBZ-UHFFFAOYSA-N 5-(2-aminoethyl)-1,3-thiazol-2-amine Chemical compound NCCC1=CN=C(N)S1 LZHGBLUAJMICBZ-UHFFFAOYSA-N 0.000 description 2
- NFOZLNMXGIFIKA-UHFFFAOYSA-N 5-(2-aminoethyl)-1,3-thiazol-2-amine;dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=C(N)S1 NFOZLNMXGIFIKA-UHFFFAOYSA-N 0.000 description 2
- BKAWJIRCKVUVED-UHFFFAOYSA-N 5-(2-hydroxyethyl)-4-methylthiazole Chemical compound CC=1N=CSC=1CCO BKAWJIRCKVUVED-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- SQCFMBWUIGQAMI-UHFFFAOYSA-N NC(N)=N.OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O.OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O Chemical compound NC(N)=N.OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O.OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O SQCFMBWUIGQAMI-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- TZNOQFCVOYXCAM-UHFFFAOYSA-N [amino(ethylsulfanyl)methylidene]-(3,3-diphenylpropyl)azanium;bromide Chemical compound [Br-].C=1C=CC=CC=1C(CC[NH+]=C(N)SCC)C1=CC=CC=C1 TZNOQFCVOYXCAM-UHFFFAOYSA-N 0.000 description 2
- 229950009330 arpromidine Drugs 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- OUJADRKXKFRDEN-UHFFFAOYSA-N guanidine dihydrobromide Chemical compound Br.Br.NC(=N)N OUJADRKXKFRDEN-UHFFFAOYSA-N 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- MURRAGMMNAYLNA-UHFFFAOYSA-N impromidine Chemical compound N1C=NC(CSCCNC(N)=NCCCC=2NC=NC=2)=C1C MURRAGMMNAYLNA-UHFFFAOYSA-N 0.000 description 2
- 229950005073 impromidine Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- SWXXKWPYNMZFTE-UHFFFAOYSA-N (c-ethylsulfanylcarbonimidoyl)azanium;bromide Chemical compound Br.CCSC(N)=N SWXXKWPYNMZFTE-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- PQAFKIUTENVXRS-UHFFFAOYSA-N 1-[2-(2-amino-4-methyl-1,3-thiazol-5-yl)ethyl]-2-(3,3-diphenylpropyl)guanidine Chemical compound N1=C(N)SC(CCNC(N)=NCCC(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C PQAFKIUTENVXRS-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N 1-butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- MFJVCEWOOPCROM-UHFFFAOYSA-N 2-[2-(2,4-dimethyl-1,3-thiazol-5-yl)ethyl]isoindole-1,3-dione Chemical compound S1C(C)=NC(C)=C1CCN1C(=O)C2=CC=CC=C2C1=O MFJVCEWOOPCROM-UHFFFAOYSA-N 0.000 description 1
- LNPILXRCRBMXCD-UHFFFAOYSA-N 2-[2-(2-amino-1,3-thiazol-5-yl)ethyl]isoindole-1,3-dione Chemical compound S1C(N)=NC=C1CCN1C(=O)C2=CC=CC=C2C1=O LNPILXRCRBMXCD-UHFFFAOYSA-N 0.000 description 1
- AGYYWZRKIJDSAW-UHFFFAOYSA-N 2-[2-(2-amino-1,3-thiazol-5-yl)ethyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.S1C(N)=NC=C1CCN1C(=O)C2=CC=CC=C2C1=O AGYYWZRKIJDSAW-UHFFFAOYSA-N 0.000 description 1
- SMRMAKJSHMWKAS-UHFFFAOYSA-N 2-[2-(2-amino-4-methyl-1,3-thiazol-5-yl)ethyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.N1=C(N)SC(CCN2C(C3=CC=CC=C3C2=O)=O)=C1C SMRMAKJSHMWKAS-UHFFFAOYSA-N 0.000 description 1
- VQVGTGLZTBUTQY-UHFFFAOYSA-N 2-[2-(4-methyl-1,3-thiazol-5-yl)ethyl]isoindole-1,3-dione Chemical compound N1=CSC(CCN2C(C3=CC=CC=C3C2=O)=O)=C1C VQVGTGLZTBUTQY-UHFFFAOYSA-N 0.000 description 1
- MYNHUKVTCJBUAO-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]-1-[3-(3,4-dichlorophenyl)-3-pyridin-2-ylpropyl]guanidine Chemical compound NC=1SC(=C(N=1)C)CCCNC(=N)NCCC(C1=NC=CC=C1)C1=CC(=C(C=C1)Cl)Cl MYNHUKVTCJBUAO-UHFFFAOYSA-N 0.000 description 1
- COBYCCIZCOQHAA-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]isoindole-1,3-dione Chemical compound N1=C(N)SC(CCCN2C(C3=CC=CC=C3C2=O)=O)=C1C COBYCCIZCOQHAA-UHFFFAOYSA-N 0.000 description 1
- YQGBOZHSFVQEPQ-UHFFFAOYSA-N 2-[3-(2-amino-4-methyl-1,3-thiazol-5-yl)propyl]isoindole-1,3-dione;hydrobromide Chemical compound Br.N1=C(N)SC(CCCN2C(C3=CC=CC=C3C2=O)=O)=C1C YQGBOZHSFVQEPQ-UHFFFAOYSA-N 0.000 description 1
- XMNSDCYVLIMUOT-UHFFFAOYSA-N 2-bromo-4-(1,3-dioxoisoindol-2-yl)butanal Chemical compound C1=CC=C2C(=O)N(CCC(Br)C=O)C(=O)C2=C1 XMNSDCYVLIMUOT-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GQAFTAYUUOBTRK-UHFFFAOYSA-N 3,5,5-trimethyl-4H-pyrazole-1-carbothioamide Chemical compound CC1=NN(C(N)=S)C(C)(C)C1 GQAFTAYUUOBTRK-UHFFFAOYSA-N 0.000 description 1
- CSJHCQDRYAUEQH-UHFFFAOYSA-N 3-(4-methyl-1,3-thiazol-2-yl)propan-1-amine;dihydrochloride Chemical compound Cl.Cl.CC1=CSC(CCCN)=N1 CSJHCQDRYAUEQH-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WMXADABRNBNSJC-UHFFFAOYSA-N 4-(1,3-dioxoisoindol-2-yl)butanal Chemical compound C1=CC=C2C(=O)N(CCCC=O)C(=O)C2=C1 WMXADABRNBNSJC-UHFFFAOYSA-N 0.000 description 1
- IOXZFXWMILDPTH-UHFFFAOYSA-N 4-(3-aminopropyl)-1,3-thiazol-2-amine Chemical compound NCCCC1=CSC(N)=N1 IOXZFXWMILDPTH-UHFFFAOYSA-N 0.000 description 1
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
- HXHGULXINZUGJX-UHFFFAOYSA-N 4-chlorobutanol Chemical compound OCCCCCl HXHGULXINZUGJX-UHFFFAOYSA-N 0.000 description 1
- AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- WMJZCJDWHBNSLB-UHFFFAOYSA-N 5-(1,3-dioxoisoindol-2-yl)pentanal Chemical compound C1=CC=C2C(=O)N(CCCCC=O)C(=O)C2=C1 WMJZCJDWHBNSLB-UHFFFAOYSA-N 0.000 description 1
- BHBQCSAJEKMSPN-UHFFFAOYSA-N 5-(2-bromoethyl)-4-methyl-1,3-thiazole;hydrobromide Chemical compound Br.CC=1N=CSC=1CCBr BHBQCSAJEKMSPN-UHFFFAOYSA-N 0.000 description 1
- RIOVLKQWIKRBIB-UHFFFAOYSA-N 5-(3-aminopropyl)-4-methyl-1,3-thiazol-2-amine Chemical compound CC=1N=C(N)SC=1CCCN RIOVLKQWIKRBIB-UHFFFAOYSA-N 0.000 description 1
- LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- NEDHHMJNFMKLBT-UHFFFAOYSA-N C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.NC=1SC(=C(N1)C)CCCNC(=N)NCCCC1=CC=CC=C1 Chemical compound C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.C1([N+](=O)[O-])=CC([N+](=O)[O-])=CC([N+](=O)[O-])=C1O.NC=1SC(=C(N1)C)CCCNC(=N)NCCCC1=CC=CC=C1 NEDHHMJNFMKLBT-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
- 230000002213 calciumantagonistic effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- OLHQOJYVQUNWPL-UHFFFAOYSA-N dimaprit Chemical class CN(C)CCCSC(N)=N OLHQOJYVQUNWPL-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- LUOYACCQSOFAAA-UHFFFAOYSA-N ethyl 6-methyl-3,6-dihydro-2h-pyran-5-carboxylate Chemical compound CCOC(=O)C1=CCCOC1C LUOYACCQSOFAAA-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 239000003386 histamine H2 receptor agonist Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- VKFHVRIEURVUHM-UHFFFAOYSA-N n-(diphenoxymethylidene)benzamide Chemical compound C=1C=CC=CC=1C(=O)N=C(OC=1C=CC=CC=1)OC1=CC=CC=C1 VKFHVRIEURVUHM-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the invention relates to new thiazole derivatives which are: a. a N-[ ⁇ -(thiazol-4 or 5-yl)alkyl]isourea, isothiourea or a guanidine derivative with formula 2 , wherein X represents a sulphur atom and Y represents a nitrogen atom or alternatively X represents a nitrogen atom and Y represents a sulphur atom, n is 1-6, R 1 represents a hydrogen atom or a straight or branched alkyl group with 1-4 carbon atoms and R 2 represents a hydrogen atom, a straight or branched alkyl group with 1-4 carbon atoms or an amino group, Z represents a sulphur atom, an oxygen atom or a NH-group respectively, R 3 represents a hydrogen atom, a phenyl or an alkyl group with 1-4 carbon atoms respectively and R 4 represents a hydrogen atom, a cyano or a benzoyl group respectively;
- R-substituted ( ⁇ -)phenyl(alkyl) groups or Q represents a R-substituted ( ⁇ -)phenyl(alkyl) group or Q represents a whether or not symmetrical mono-or disubstituted methylidene fragment, wherein R 1 represents a R-substituted (10,11-dihy- dro) optionally aza 5H-dibenzo-[a,d]-cyclohepten-5-yl group or R' represents two whether or not symmetrically with R substituted phenyl groups, wherein R represents hydro
- R-substituted phenyl rings may be replaced by a (heterocyclic) (aromatic) ring whether or not R-substituted or by a combination of a (condensed) (aromatic) (heterocyclic) R-substituted ring with one or more (condensed) (aromatic) (heterocyclic) rings whether or not symmetrically R-substituted.
- R-substituted (condensed) (heterocyclic) (aromatic) rings are for example: 2-, 3-, 4-pyridyl, 2-, 4-, or 5-pyrimidinyl, 2-, 3-, 4-[dihydro]pyridyl, 4- or 5-imidazolyl, 2-, 4- or 5-thiazolyl, 2- or 3-furyl, 2- or 3-thienyl, dihydropyridazinon-2 or 6-yl, 2-benzoimidazolyl, etc.
- the invention also relates to the acid addition salts of the compounds with the formulas 2 and 3.
- Histamine receptors are classified according to the present knowledge into three categories which are described, mainly for historical reasons, with the qualifications of H 1 - , H 2 - and H 3 -receptor.
- Each of these classes of receptors presumably has its own and biologically specific function, in as far as they are present and dependent on the location of such a receptor type in the organism involved.
- a treatment with endogenous or exogenous compounds may be necessary which may stimulate (agonistic activity) or inhibit (antagonistic activity) the receptor system. From the above follows the great importance of compounds capable to agonize or to antagonize in a selective way the different classes of histamine receptors.
- histamine H 2 -receptor active, compounds It is important to be able to dispose of selective histamine receptor active compounds in order to discriminate between the different receptor types not only from a scientific (pharma-cological) point of view, but also on therapeutic respect notably the stimulation of the histamine H 2 -receptor offers wide perspectives for the treatment of congestive heart diseases, accompanied by heart failure, and certain allergic disorders so that there exists a large interest from within the pharmaceutical industry for the development and application of selective, histamine H 2 -receptor active, compounds.
- Impromidine (5) described by G.J. Durant et al. in Nature 276, p.403-405 (1978) and Dimaprint (6), described by C.R. Ganellin in Pharmacology of Histamine Receptors, p.40-44 (1982), publishers Wright.PSG., exhibit a moderately to fairly high affinity for the histamine H 2 -receptor.
- Impromidine (5) the most active guanidine derivatives of formula 7 and Arpromidine (8) all contain under physiological circumstances a protonated N-[3-(imidazol-4-yl)propyl]- guanidine fragment.
- the imidazole moiety can be replaced by a (substituted)aminothiazole.
- the invention also relates to a process for the preparation of a ⁇ -aminoalkylthiazole derivative in which one prepares a histamine H 2 -receptor active compound, whether or not in combination with an additionally wanted biological activity, by preparing from a compound with formula 1 or its acid addition salt a compound with a substituted 4- or 5-( ⁇ - thiazoly1-alkyl) guanidine fragment.
- Examples of such compounds are the compounds with formulas 2 and 3 and their acid addition salts.
- Additional substitution at the other nitrogen atom may be applied in order to change the activity for the H 2 -receptor into an antagonistic activity.
- the 2- amino-5-(2-aminoethyl)-4-methylthiazole (12) can be displaced competitatively by cimetidine, while the intrinsic activity (related to the chronotropic effect) is equal to that of histamine, thus rendering it to be a full agonist for the H 2 - receptor with an activity twice as high as that of histamine.
- the 2-amino-5-(3-aminopropyl)-4-methylthiazole (26b) is a full H 2 -receptor agonist with an activity 30 times as high as that of the corresponding 4 (5)-3-aminopropyl)-imidazole.
- the 2-amino-5-(2-aminoethyl)-4-methylthiazole (12) shows however contrary to histamine (13), in the testing systems used not a single activity towards the H 1 and H 3 -receptors.
- the essence of the invention now relates to the replacement of the N-[3-(imidazol-4-yl)propyl]guanidine fragment (9) from the previously mentioned different classes of H 2 -receptor active compounds with i.a. other combined H 1 -receptor antagonistic, calcium antagonistic, phosphodiesterase inhibitory activity etc, by the more H 2 -receptor specific and more active N-[3-(substituted thiazol-4 or 5-yl)propyl]guanidine fragments.
- the thiazole derivatives with formulas 2-4 thus obtained show a high to very high activity on the H 2 -receptor.
- the 4- or 5-( ⁇ -aminoalkyl) thiazole derivatives mentioned in the introduction with formula 1 may be obtained using a process not previously described in the literature in high yields by ring closure of a 2-bromo- ⁇ -phthalimidoalkanal (18), a 3-bromo- ⁇ -phthalimidoalkan-2-one (24) or a 1-bromo- ⁇ - phthalimidoalkan-2-one (27) with thioformamide, an alkylthioamide or thiourea in dimethylformamide under mild conditions, followed by hydrazinolysis or hydrolysis with diluted hydrochloric acid of the resulting phthalimido derivatives (19, 25 or 28) as depicted in reaction schemes A and B.
- reaction scheme A one uses as starting materials for the preparation of the 2-bromo- ⁇ -phthalimidoalkanals (18) ⁇ -phthalimidoalkanols (16) which may be obtained using processes known from the literature. Conversion of these ⁇ -phthalimidoalkanols (16) into the corresponding aldehydes (17) is being carried out according to a general method using oxalylchloride/dimethylsulphoxyde, followed by proton abstraction with a mild base such as triethylamine followed by hydrolysis with water as described by K.Omura et al. in Tetrahedron 34, p. 1651-1660 (1978).
- the necessary ⁇ -haloketones (22) which are to be used for the preparation of the 1- and 3-bromo- ⁇ -phthalimidoalkan-2-ones (24 and 27) are either commercially available or may be obtained in good yield according to a process described in the literature such as for example the process described in the Dutch patent application 65 11581.
- N-[ ⁇ -(thiazol-4 or 5-yl) alkyl] isourea or isothiourea derivatives with formula 2 are obtained by reaction of a 4- or 5-( ⁇ -aminoalkyl)thiazole with formula 1, with a dialkyl-N- cyano-iminodithiocarbonate, a diphenyl-N-cyanocarbonimidate or a diphenyl-N-benzoylcarbonimidate respectively in a suitable solvent according to methods known from the literature and as indicated in reaction scheme C.
- N-[ ⁇ -(thiazol-4 or 5-yl) alkyl]guanidine derivatives are obtained by reacting a 4- or 5-( ⁇ -aminoalkyl)thiazole with formula 1 together with a S-alkylisothiouronium derivative.
- the N-[ ⁇ -(thiazol-4 or 5-yl)alkyl]isourea or isothiourea derivatives thus obtained (32) are condensed with a suitable amine (33).
- N-( ⁇ -substituted alkyl)-N'- subtituted-N"-[ ⁇ -(thiazol-4 or 5-yl)alkyIguanidines with formula 3 (34) thus obtained are purified and subjected to a mild hydrolysis in diluted hydrochloric acid following which the resulting N-( ⁇ -substituted alkyl)-N'-[ ⁇ -(thiazol-4 or 5-yl) alkyl] -guanides with formula 4 (35) can be obtained in good yield eventually after conversion to a suitable acid addition salt.
- N-( ⁇ -substituted alkyl)-N'substituted-N"-[ ⁇ -(thiazol-4 or 5-yl)alkyl]guanidines with formula 3 may be obtained by reacting a 4- or 5-( ⁇ -aminoalkyl)thiazole with formula 1 together with the corresponding N-( ⁇ -substituted alkyl) isourea or isothiourea derivatives (36) according to methods known from the literature and as indicated in reaction scheme D or by condensation of a 4- or 5-( ⁇ -aminoalkyl)thiazole with formula 1 with a N-( ⁇ -substituted alkyl)-S- alkylthiouronium derivative (41) as indicated in reaction scheme E.
- the invention also relates to a medicament or a scientific (pharmacological) adjuvant which contains as the active ingredient a compound according to one of the formulas 2-3 or an acid addition salt thereof.
- a medicament or a scientific (pharmacological) adjuvant which contains as the active ingredient a compound according to one of the formulas 2-3 or an acid addition salt thereof.
- Melting points were determined by a Mettler FP 5 device for the determination of melting points.
- Mass spectra are determined on a Varian Mat CH 5 spectrometer or on a Mat 90 (Finnigan Mat, San Jose, U.S.A.).
- chloroform phase is hjgh-vacuum concentrated.
- the reaction mixture the inorganic salts are filtered off and the precipitate s rinsed with a little cold methanol, subsequently the filtrate is vacuum concentrated.
- dichloromethane is dropwise added at such a rate that the temperature is maintained at -50°C. After the addition the stirring is continued for 15 minutes, subsequently a solution of 0.40 mole of an appropriate ⁇ -phthalimido-1-alkanol (16) in circa 400 ml of dry dichloromethane is dropwise added at such a rate that the temperature is maintained at -50°C. After the addition the stirring is continued at -50°C for 30 minutes, subsequently 222 g (2.20 mole) of triethylamine is added thereto. Subsequently the cooling is removed and the reaction mixture is slowly brought with stirring at room temperature, thereafter circa 1250 ml of demineralized water is added.
- reaction mixture is high vacuum concentrated. Subsequently a little ethanol is added to the residue, it is stirred for 30 minutes, thereafter the crystalline material is filtered off, washed with subsequently ethanol and diethylether, thereafter the precipitate is vacuum dried. If necessary it is recrystallized from an appropriate solvent.
- the product was crystallized from an ethanol/methanol mixture.
- 6-Bromo-2-hexanone (22a) is prepared according to a modified process as described in Dutch patent application 6511581 dated March 7,1966, cf. Chem. Abstr. 65, P20151d.
- a mixture of 552 g (4 mole) of particulated anhydrous potassium carbonate, 404 g (2 mole) of freshly distilled 1,3- dibromopropane, 260g (2 mole) of freshly distilled acetyl acetic ester and 700 ml of absolute ethanol is heated with vigorous stirring until circa 60°C. After the mild exothermal reaction beginning at circa 50°C, the reaction mixture is refluxed for circa 5 hours. After cooling the reaction mixture the inorganic salts are filtered off and the residue is rinsed with absolute ethanol. The combined filtrates are subsequently vacuum concentrated, thereafter to the residue circa 250 ml of demineralized water is added. Subsequently it is extracted with toluene. The collected toluene phases are combined, dried on anhydrous sodium sulfate, filtered and subsequently vacuum concentrated.
- Boiling point 102-106°C/18 mm Hg Reference: (Chem. Abstr., 65, P 20151d).
- Mass spectrum M/Z (intensity in %) . 180(0.14): 178(0.11);
- the 4-phthalimido-2-butanone (23a) was prepared according to a modified process by H. Irai et al., Kogyo Kagaku
- the 5-phthalimido-2-pentanone ( 23a) is prepared according to Dutch patent app lication 8800998 , April 18 , 1988.
- the 6-phthalimido-2-hexanone (23b) is prepared as described for the 5-phthalimido-2-pentanone (23a) in Dutch patent application 8800998, April 18,1988.
- the 1-bromo- ⁇ -phthalimido-2-alkanones (27) are prepared according to Dutch patent application 8800998, April 18,1988.
- the 4-( ⁇ -phthalimidoalkyl)thiazoles (28) are prepared as described for the 5-( ⁇ -phthalimidoalkyl)thiazoles (25) in example IX.
- Mass spectrum M/Z (intensity in %): 143 (19.3); 127(3.4); 114 (100).
- Mass spectrum M/Z (intensity in %): 157.(13.3): 141 (53.6); 127(100); 113 (9.5).
- Mass spectrum M/Z (intensity in %) : 171(28.9); 154(75.1); 127(100); 115(9.7).
- Mass spectrum M/Z (intensity in %): 143(4.4); 127(9.9);
- Mass spectrum M/Z (intensity in %): 143(12.4); 126(6.8);
- the 5-(2-(aminoethyl)-4-methylthiazoledihydro- chloride (26c) may, if desired, also obtained in the following manner: A solution of 25.0 g (o,175 mole) of 5-(2-hydroxyethyl)- 4-methylthiazole (Fluka A.G., Chem. Fabrik, CH-9470 Buchs) in 150 ml of aqueous-48% hydrogen bromide solution is refluxed for 48 hours. After cooling the reaction mixture is
- the 1 H-NMR-spectrum is identical to the spectrum as obtained with the preparation of the 5-(2-aminoethyl)-4-methylthiazole- dihydrochloride (26c) as described in example Xllg.
- the precipitate obtained is subsequently filtered off and washed
- the viscous oil obtained comprising crude N-[2-(2-amino-4- methylthiazole-5-yl)ethyl]-N'-cyano-N"-(3,3-diphenylpropyl)- guanidine (34a) is subsequently taken up without any purification in 100 ml of 2N aqueous hydrochloric acid, thereafter there is refluxed for 3 hours. After cooling there is vacuum concentrated and the residue dissolved in absolute methanol. After filtration a solution of 0.02 mole of
- N-[3-(2-amino-4-methylthiazole-5-yl)propyl]- N'-(3,3-diphenylpropyl)guanidine (35b) was prepared in a manner analogous to that of the N-[2-(2-amino-4-methyl- thiazole-5-yl)ethyl]-N'-(3,3-diphenylpropyl)guanidine (35a), as described in example XVIIIa, from N-cyano-N'-(3,3- diphenylpropyl)-0-phenylisoureum (37a) and 2-amino-5-(3- aminopropyl)-4-methylthiazole dihydrochloride (26b) with the proviso that the reaction mixture was refluxed for
- reaction mixture is decolorised with activated carbon, filtered and vacuum concentrated. The residue is subsequently taken up in 100 ml of 2N aqueous hydrochloric acid
- the viscous oil obtained comprising N-[3-(2-amino-4-methylthiazole-5-yl)propyl]-N'- cyano-N"-(3,3-diphenylpropyl)guanidine (34b) is hydroly zed after column chromatography (Kieselgel 60-80, eluent
- a solution of 1.34 g (0.005 mole) of N-[3-(2-amino- 4-methy1thiazole-5-yl)propyl]-N'-cyano-S-methylisothioureum (32c) and 1.41 g (0.005 mole) of 2-[3-amino-1-(3,4-dichlorophenyl)propyl]pyridine* in circa 50 ml of pyridine is
- demineralized water is added thereto and the precipitate obtained is filtered off, then recrystallized from a methanol/water mixture.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL9000132 | 1990-01-19 | ||
NL9000132A NL9000132A (nl) | 1990-01-19 | 1990-01-19 | Nieuwe thiazoolderivaten. |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0511270A1 true EP0511270A1 (en) | 1992-11-04 |
Family
ID=19856444
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91902805A Withdrawn EP0511271A1 (en) | 1990-01-19 | 1991-01-18 | Thiazole derivatives |
EP91902804A Withdrawn EP0511270A1 (en) | 1990-01-19 | 1991-01-18 | New thiazole derivatives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91902805A Withdrawn EP0511271A1 (en) | 1990-01-19 | 1991-01-18 | Thiazole derivatives |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP0511271A1 (nl) |
JP (2) | JPH05503096A (nl) |
AU (2) | AU7058191A (nl) |
CA (2) | CA2074180A1 (nl) |
IE (2) | IE910172A1 (nl) |
IL (2) | IL96997A0 (nl) |
NL (1) | NL9000132A (nl) |
WO (2) | WO1991010657A1 (nl) |
ZA (2) | ZA91418B (nl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1713780B1 (en) * | 2004-02-05 | 2012-01-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2636037A (en) * | 1947-10-10 | 1953-04-21 | Sharp & Dohme Inc | 2-amino-4-piperidinoethyl-thiazole |
FR2073427A1 (en) * | 1969-11-28 | 1971-10-01 | Sogeras | 4-methyl-5-ethyl-n-heterocyclic thiazoles - with antianoxic activity |
FR2361111A1 (fr) * | 1976-08-11 | 1978-03-10 | Roussel Uclaf | Nouveaux derives de 5-thiazole alkylamine, un procede pour leur preparation et leur application comme medicaments |
US4166860A (en) * | 1977-10-11 | 1979-09-04 | William H. Rorer, Inc. | Imidazole amidinoureas for stimulating H2 -receptors |
US4474794A (en) * | 1982-03-19 | 1984-10-02 | Eli Lilly And Company | N-Thiazolylmethylthioalkyl-N1 -alkenyl (or alkynyl)guanidines and related compounds |
NL8601585A (nl) * | 1986-06-19 | 1988-01-18 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | N-(2-gesubstitueerde alkyl)-n-imidazol-4-yl alkyl guanidine. |
NL8800998A (nl) * | 1988-04-18 | 1989-11-16 | Cedona Pharm Bv | Werkwijze voor het bereiden van een al of niet gesubstitueerd 4(5)-(omega-aminoalkyl) imidazool. |
-
1990
- 1990-01-19 NL NL9000132A patent/NL9000132A/nl not_active Application Discontinuation
-
1991
- 1991-01-18 EP EP91902805A patent/EP0511271A1/en not_active Withdrawn
- 1991-01-18 AU AU70581/91A patent/AU7058191A/en not_active Abandoned
- 1991-01-18 JP JP3502574A patent/JPH05503096A/ja active Pending
- 1991-01-18 CA CA002074180A patent/CA2074180A1/en not_active Abandoned
- 1991-01-18 CA CA002074175A patent/CA2074175A1/en not_active Abandoned
- 1991-01-18 IE IE017291A patent/IE910172A1/en unknown
- 1991-01-18 AU AU70644/91A patent/AU7064491A/en not_active Abandoned
- 1991-01-18 IE IE017191A patent/IE910171A1/en unknown
- 1991-01-18 EP EP91902804A patent/EP0511270A1/en not_active Withdrawn
- 1991-01-18 WO PCT/NL1991/000008 patent/WO1991010657A1/en not_active Application Discontinuation
- 1991-01-18 WO PCT/NL1991/000007 patent/WO1991010656A1/en not_active Application Discontinuation
- 1991-01-18 JP JP3502573A patent/JPH05503694A/ja active Pending
- 1991-01-21 ZA ZA91418A patent/ZA91418B/xx unknown
- 1991-01-21 ZA ZA91419A patent/ZA91419B/xx unknown
- 1991-01-22 IL IL96997A patent/IL96997A0/xx unknown
- 1991-01-22 IL IL96998A patent/IL96998A0/xx unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9110657A1 * |
Also Published As
Publication number | Publication date |
---|---|
ZA91419B (en) | 1991-10-30 |
NL9000132A (nl) | 1991-08-16 |
WO1991010657A1 (en) | 1991-07-25 |
AU7058191A (en) | 1991-08-05 |
JPH05503694A (ja) | 1993-06-17 |
AU7064491A (en) | 1991-08-05 |
CA2074175A1 (en) | 1991-07-20 |
WO1991010656A1 (en) | 1991-07-25 |
IE910172A1 (en) | 1991-07-31 |
IL96998A0 (en) | 1992-03-29 |
IE910171A1 (en) | 1991-07-31 |
EP0511271A1 (en) | 1992-11-04 |
CA2074180A1 (en) | 1991-07-20 |
IL96997A0 (en) | 1992-03-29 |
JPH05503096A (ja) | 1993-05-27 |
ZA91418B (en) | 1991-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR860001818B1 (ko) | 2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조 방법 | |
Turner et al. | Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1, 3, 4-thiadiazoles | |
AU665256B2 (en) | Branched alkylamino derivatives of thiazole, processes for preparing them and pharmaceutical compositions containing them | |
US4560690A (en) | 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents | |
NO329617B1 (no) | Tiazolderivater med CB1-antagonistisk, agonistisk eller partiell agonistisk aktivitet | |
HU206709B (en) | Process for producing new 3-/4-/1-substituted-4-piperazinyl/-butyl/-4-thiazolidinone derivatives and pharmaceutical compositions containing them | |
KR19990037102A (ko) | 아미드 유도체 및 이의 염 | |
NO158419B (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,2-diaminocyklobuten-3,4-dioner. | |
HU181960B (en) | Process for producing substituted imidazolylmethylthio-compounds | |
EP0234011B1 (en) | 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines | |
UA73125C2 (uk) | Похідні амінотіазолу, спосіб їх одержання, фармацевтична композиція та їх використання як лігандів рецептора crf | |
DE69119979T2 (de) | Pyrrolderivate | |
NO885117L (no) | Substituerte hydroksylaminer. | |
EP0511270A1 (en) | New thiazole derivatives | |
US4935424A (en) | 4 or 5-(substituted piperazinylalkyl)-2-aminothiazoles as antipsychotic agents | |
IE42210B1 (en) | 2-methoxy-benzamide derivatives | |
US4673677A (en) | Method for treatment of gastrointestinal disorders | |
HU209890B (en) | Process for producing n-substituted 2-aminomethyl-2,3-dihydro-pyrano[2,3-b]pyridine derivatives | |
US4738960A (en) | 1,3,4-Thiadiazole derivatives and pharmaceutical preparations useful as inhibitors for histamine-H2 receptors | |
US3446797A (en) | N-(2-propynyl) nitrogen-containing heterocyclic compounds | |
Shafik et al. | Synthesis of novel 2-[2-(substituted amino) phenethyl]-1H-benzimidazoles; 3, 4-dihydro and 1, 2, 3, 4,-tetrahydropyrimido [1, 6-a]-benzimidazoles as potential antiulcer agents | |
CS239926B2 (en) | Precessing of (2-thienyl)-and 2-(3-thienyl) ethylamine derivatives | |
NO148556B (no) | Analogifremgangsmaate for fremstilling av farmakologisk aktive triazinoner. | |
FR2536399A1 (fr) | Derives de thiazole et leur procede de preparation | |
EP0186275A2 (en) | 2-Substituted amino-4(1H)-pyrimidone derivatives, their production, and medical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19920710 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19930906 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19940118 |